These results provided evidence that the compound could address cognition-relevant neural dysfunction
There is no way to know which category you fall into without trying
For musculoskeletal injuries, the best evidence supports structured rehabilitation and progressive loading through exercise programs designed by physiotherapy and sports medicine professionals
Separately, FDA lists GHK-Cu for injectable routes under safety concerns, citing immunogenicity risk and limited human safety data [8]
Promotion of Neurogenesis By stimulating the growth of new neurons (neurogenesis), Dihexa contributes to the overall health and functionality of the brain, which is crucial for cognitive processes
Assuming Eli Lilly follows a similar timeline to tirzepatide, the earliest possible FDA approval for retatrutide would likely occur in late 2027 or 2028, depending on Phase 3 trial results and regulatory review timelines